Modifiedpriority healthPolicy N/A

Parenteral Nutritional Therapy (PN) Coverage Criteria

Defines medical necessity, prior authorization, inclusions, exclusions, and governmental guidance for parenteral nutrition (including home PN and intradialytic PN) for Priority Health members.

Policy Summary

Payerpriority health

PolicyParenteral Nutritional Therapy (PN) Coverage Criteria

Policy CodePolicy N/A

Change TypeAdded exclusionsupdated governmental routing for Medicare requests

Effective DateSep 1, 2025

Next Review DateN/A

Key ActionSubmit initial home PN prior authorization for up to 3 months and request continuing authorization at least every 3 months; route Medicare authorization requests to Pharmacy.

SourceLink

POLICY UPDATE CHANGES

Added section I. C. Exclusions

Added section II. GOVERNMENTAL REGULATIONS with instructions that Medicare coverage authorization requests for Parenteral Nutrition should be submitted to the Pharmacy department

Deleted prior note incorporating Intradialytic Parenteral Nutrition (IDPN) criteria from an ESRD policy

Restructured section I. POLICY/CRITERIA for enhanced clarity

3 monthsinitial home PN prior authorization period

6 monthsIDPN re-evaluation interval

<3.4 g/dlserum albumin threshold

20-40 kcal/kgdaily adult caloric guideline

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Parenteral Nutrition

Home Parenteral Nutrition — Initial eligibility

Home parenteral nutrition may be considered medically necessary when BOTH of the following are met:

Home PN primary criteria

a. Malabsorptive condition: Structural or functional gastrointestinal tract disease or condition resulting in insufficient absorption of nutrients to maintain adequate strength and weight that cannot be corrected by modifying the enteral/oral diet or by pharmacologic treatment
Examples include, but are not limited to: Crohn's disease; newborns with catastrophic GI anomalies (eg, tracheoesophageal fistula, gastroschisis, omphalocele, massive intestinal atresia); infants/children with short bowel syndrome or chronic idiopathic diarrhea leading to failure to thrive; short bowel syndrome after massive resection; prolonged paralytic ileus after major surgery or trauma; radiation enteritis; chronic or severe acute pancreatitis when tube feeding cannot be placed or tolerated; hyperemesis gravidarum when tube feeding cannot be placed or tolerated; obstruction not bypassable by tube feeding; malabsorption from enteric fistulas; motility disorders (pseudo-obstruction).
b. Nutritional/lab or feeding failure criteria: At least one of the following must be present
i. >10% unintentional loss of body weight over three months or less; ii. Serum albumin concentration < 3.4 g/dl; iii. Clinical record demonstrates the patient cannot be maintained on enteral feedings. Note: Botulinum toxin and TPN will not be authorized together for treatment of gastroparesis.

Intradialytic Parenteral Nutrition (IDPN) — Eligibility

IDPN (including IPN) may be considered medically necessary when ALL of the following apply:

IDPN eligibility

a. ESRD: Member has end stage renal disease (ESRD)
b. Nutritional criteria: One of the following nutritional/lab findings is present
i. Serum albumin < 3.4 g/dl; OR ii. Protein < 6 g/dl AND one of: BMI < 18.5 kg/m2; unintentional weight loss >10% within last 6 months; OR BMI < 20 kg/m2 and unintentional weight loss >5% within last 3–6 months. Clinical re-evaluation is required after six months for consideration of continued treatment.

IDPN clinical evidence summary

Coverage stance and key clinical notes

IDPN evidence summary: Retrospective comparative studies suggest IDPN for up to 1 year may reduce mortality in malnourished hemodialysis patients, but a single prospective randomized study showed no mortality benefit for 1 year of IDPN plus oral supplementation versus oral supplementation alone.

IDPN may offer advantages for certain subpopulations, but prospective studies are needed to define those groups.

Excluded: Consumer-directed IV wellness therapies

Explicit noncoverage

Consumer IV wellness therapies excluded: IV wellness therapies marketed or administered without a prescription or physician approval, and those whose providers state the services are not FDA‑evaluated or that insurance does not cover them (eg, certain direct‑to‑consumer 'drip' services), are considered not medically necessary and excluded from coverage.

Examples include entities that ship products directly to consumers or administer treatments without a prescription or doctor approval, or state products are not intended to diagnose, treat, cure, or prevent disease.

Parenteral nutritional therapy provided at home is intended to treat medically documented malabsorptive or absorptive failure when the gastrointestinal tract cannot provide adequate nutrition. It is not medically necessary for purposes such as increasing protein or caloric intake in addition to a patient’s normal diet, or for routine pre‑ or postoperative care. Specific examples of clinical situations where home IV PN is not indicated include patients with functioning GI tracts whose intake problems are due to anorexia from cancer, swallowing disorders, temporary gastric emptying defects (eg, metabolic or electrolyte causes), psychological disorders impairing intake, physical limitations (eg, severe pulmonary or cardiac disease), medication side effects, or renal failure/dialysis.

When home PN is provided, authorization and documentation requirements apply: equipment, supplies, and medically necessary nutrients may be covered when criteria are met, but initial authorizations will not exceed three months and continuing authorization is required at least every three months. Clinical records must support that the patient meets qualifying malabsorptive or feeding‑failure criteria (for example, >10% unintentional weight loss over three months, serum albumin < 3.4 g/dl, or inability to be maintained on enteral feedings).

Some consumer‑directed companies market and administer intravenous “wellness” therapies directly to consumers. These services commonly do not require a prescription or a physician’s approval, and vendors may state that their products or services are not evaluated by the Food and Drug Administration or that insurance does not cover them. Because these therapies are offered outside the usual medical oversight and documentation processes required for medically necessary care, they are excluded from coverage.

Providers should be aware that supplies or services obtained from entities that explicitly state insurance does not cover their therapies, or that do not require a prescription or doctor approval, are at risk for denial as not medically necessary.

IV wellness treatments marketed directly to consumers (for example, ‘drip’ services) may be shipped to the consumer or administered in the consumer’s home or at a company facility. These offerings typically lack standard physician prescription or oversight and vendors often characterize products as not intended to diagnose, treat, cure, or prevent disease or as not evaluated by the FDA.

Because these consumer‑directed IV therapies do not meet the medical necessity requirements for parenteral nutrition or other clinically indicated intravenous treatments, they are considered not medically necessary and are not covered under this policy.

Intravenous consumer‑directed “wellness” therapies that are marketed or administered without a prescription or physician approval and/or that vendors state have not been evaluated by the FDA are not medically necessary and are expressly excluded from coverage.

Any claims for IV treatments or services obtained from entities that require no physician prescription or that indicate their products/services are not covered by insurance should be expected to be denied as excluded, not medically necessary services.

Coding — Diagnosis and Procedure Codes

Nutritional / laboratory thresholds

Provider Actions, Authorization, and Documentation

Prior Authorization

Prior authorization and re-evaluation

Initial home PN authorization will not exceed three months. Clinical re-evaluation for continued parenteral nutrition is required at least every three months for home PN and after six months for intradialytic/parenteral nutrition (IDPN/IPN). Providers must submit prior authorization requests demonstrating medical necessity and provide clinical records supporting ongoing need at each re-evaluation.

Initial authorization period: up to 3 months (home PN)
Re-evaluation/continuation: at least every 3 months (home PN)
IDPN/IPN re-evaluation: clinical review required after 6 months

Billing Rule

Prior authorization may be required for listed TPN and supply codes

Background and Scope

Parenteral nutritional therapy delivers macronutrients, micronutrients, fluids, and electrolytes intravenously when the gastrointestinal tract cannot be used or cannot provide adequate nutrition. It may be administered centrally or peripherally and is intended to prevent or correct nutrient deficiencies and malnutrition when oral or enteral feeding is impossible, contraindicated, or insufficient.

Intradialytic Parenteral Nutrition (IDPN) is a specialized form of PN given during hemodialysis or via existing dialysis access for patients with end‑stage renal disease who have protein‑energy malnutrition. IDPN may be considered for select ESRD patients, although evidence of mortality benefit is mixed and prospective studies are needed to define subpopulations most likely to benefit.

Definitions

Parenteral Nutritional Therapy (PNT) — definition

DefinitionParenteral Nutritional Therapy (PNT): intravenous administration of nutrients via central or peripheral vein, bypassing the gastrointestinal tract when oral or enteral feeding is not possible or sufficient.

IndicationUsed to prevent or correct nutrient deficiencies and malnutrition when the GI tract cannot be used effectively or safely.

RouteDelivered through central or peripheral venous access and includes necessary supplies and equipment when criteria are met.

Intradialytic Parenteral Nutrition (IDPN) — definition & context

DefinitionIntradialytic Parenteral Nutrition (IDPN): a specialized form of parenteral nutrition administered during dialysis sessions to treat protein-calorie malnutrition in patients with end-stage renal disease (ESRD).

Administration